anti-EGFR targeting mAbs nanomAb (Immune Pharmaceuticals)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-EGFR targeting mAbs nanomAb (Immune Pharmaceuticals)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists

TargetsEpidermal growth factor receptor erbB1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIsrael

CombinationsNo

Global Highest StatusSuspended

Highest Status in ChinaN/A

Originator CompaniesImmune Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesImmune Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A